跳到正文
FDA 官方药品与生物制品信息·精选AI 评分68

FDA发布MAPP 5310.3 Rev. 2,规定CMC变更相关NDA和BLA补充申请的加快审评政策

MAPP 5310.3 Rev. 2 Requests for Expedited Review of New Drug Application and Biologics License Application Prior Approval Supplements Submitted for Chemistry, Manufacturing, and Controls Changes

AI 导读

FDA药品质量办公室(OPQ)发布MAPP 5310.3 Rev. 2,规定对涉及CMC变更并由OPQ管理的NDA和BLA补充申请(PAS)加快审评请求的授予或拒绝政策。

推荐理由

文件列出OPQ对涉及CMC变更的NDA和BLA补充申请加快审评的受理情形与职责分工,可供了解FDA内部审评优先级判定依据。

正文 · 原文

PDF 文字版;图形和原始排版请参阅官方 PDF。

第 1 页

MANUAL OF POLICIES AND PROCEDURES

CENTER FOR DRUG EVALUATION AND RESEARCH                                                           MAPP 5310.3 Rev. 2


                                                     POLICY

                       OFFICE OF PHARMACEUTICAL QUALITY

  Requests for Expedited Review of New Drug Application and Biologics License
Application Prior Approval Supplements Submitted for Chemistry, Manufacturing,
                             and Controls Changes


                                              Table of Contents

                 PURPOSE ..............................................................................1
                 POLICY .................................................................................1
                 RESPONSIBILITIES ...........................................................4
                 REFERENCES......................................................................5
                 EFFECTIVE DATE ..............................................................5
                 CHANGE CONTROL TABLE............................................5

PURPOSE

This MAPP outlines the policies of the Office of Pharmaceutical Quality (OPQ) for
granting or denying a request to conduct an expedited review for new drug application
(NDA) and biologics license application (BLA) prior approval supplements (PASs) with
Prescription Drug User Fee Act (PDUFA) goal dates that (1) involve chemistry,
manufacturing, and controls (CMC) changes and (2) are managed by OPQ. 1 This MAPP
specifies both the criteria that OPQ uses to make an expedited review designation and the
roles and responsibilities of the OPQ quality assessment team members for making this
designation.


POLICY

    •   In this MAPP, an expedited review means that OPQ will strive to assess and act
        on the PAS before the PDUFA goal date associated with that PAS. It should be
        noted, however, that an expedited review designation for either an NDA PAS or a
        BLA PAS does not change the PDUFA goal dates associated with that PAS.

    •   If a public health need arises, OPQ may designate the PAS for expedited review
        with or without a request from an applicant. The scope of this MAPP includes


1
Although OPQ also manages certain abbreviated new drug application (ANDA) supplements, these
supplements should be prioritized according to MAPP 5240.3 Rev. 6 Prioritization of the Review of
Original ANDAs, Amendments, and Supplements.

Originating Office: Office of Pharmaceutical Quality
Effective Date: 6/10/1999; 5/21/2018; 4/8/2021
                                                                                                             Page 1 of 5

第 2 页

MANUAL OF POLICIES AND PROCEDURES

CENTER FOR DRUG EVALUATION AND RESEARCH                                             MAPP 5310.3 Rev. 2

        both expedited review requests received internally and from an NDA or BLA
        applicant.

    •   OPQ will consider requests from an applicant for an expedited review of a PAS
        on a case-by-case basis. However, OPQ will only consider expedited review
        requests that clearly state the basis for the request.

    •   OPQ may designate a PAS for expedited review at the time it receives the PAS or
        anytime thereafter. If the OPQ quality assessment team receives a request for
        expedited review after OPQ has received and initially processed the PAS, OPQ
        will consider the request and may expedite the review of that PAS, as appropriate.

    •   If OPQ grants an expedited review for a PAS, that PAS’s review completion date
        will depend on both the availability of OPQ’s resources and the provisions of the
        PAS.

    •   If OPQ determines that a multidisciplinary team should participate in the
        assessment of a PAS designated for expedited review, the OPQ Office of Program
        and Regulatory Operation’s Regulatory Business Project Manager (OPQ RBPM)
        will notify all appropriate assessment divisions and inspection divisions of the
        need to expedite the PAS.

    •   OPQ will not consider a request for an expedited review that involves a facility
        that is subject to a recommendation of Official Action Indicated, unless an
        expedited review will help address a public health concern. The OPQ RBPM and
        appropriate OPQA supervisor, in consultation with other personnel as necessary,
        will determine if FDA must expedite the review to address the public health
        concern.

    •   OPQ will consider an expedited review request for a PAS that falls into one or
        more of the following categories:
        o Drug shortages: Submissions that could help mitigate or resolve a drug
          shortage 2 or prevent future shortages will, as appropriate, receive an expedited
          review. 3

        o Special review programs: Submissions that are subject to a special review
          program, such as the President’s Emergency Plan for AIDS Relief, may
          receive expedited review.

2
  This includes drug products on the drug shortage list confirmed by the CDER Drug Shortages Staff. For a
list of current and resolved drug shortages and discontinuations of drugs and biologics regulated by CDER,
see https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm.
3
  As described in section 506C(g)(1) of the Federal Food, Drug, and Cosmetic Act, the FDA shall, as
appropriate, prioritize and expedite the review of ANDAs and supplements for NDAs and ANDAs that
could help to prevent or mitigate certain drug shortages.

Originating Office: Office of Pharmaceutical Quality
Effective Date: 6/10/1999; 5/21/2018; 4/8/2021
                                                                                              Page 2 of 5

第 3 页

MANUAL OF POLICIES AND PROCEDURES

CENTER FOR DRUG EVALUATION AND RESEARCH                                     MAPP 5310.3 Rev. 2


        o Public health emergencies: Submissions that could help address a public
          health emergency declared by the Secretary of the U.S. Department of Health
          and Human Services, or anticipated under the same criteria, may receive
          expedited review.
        o Certain government purchasing programs: Submissions related to certain
          government purchasing or procurement activities, including expiration-date
          extensions or packaging changes usually requested by the Government-Wide
          Quality Assurance Program, may receive expedited review.
        o Statutory mandates or other legal requirements: Submissions that are subject
          to Federal or State mandates or other legal (e.g., regulatory) actions may
          receive expedited review as necessary to comply with those requirements.
          Please note: This category also includes any legally required changes in
          formulation or labeling. However, PASs submitted under 21 CFR
          314.70(b)(4) or 601.12(b)(4) in response to feedback from FDA about CMC
          changes that were not reported appropriately (e.g., certain CMC changes
          reported to an application as a changes being effected supplement rather than a
          PAS) will not be considered for expedited review.

        o Extraordinary hardship on the applicant: Under 21 CFR 314.70(b)(4) or
          601.12(b)(4), an applicant “may ask FDA to expedite its review of a
          supplement for public health reasons or if a delay in making the change
          described in it would impose an extraordinary hardship on the applicant.”
          Submissions received from an applicant who has experienced one or more of
          the following extraordinary hardships may receive expedited review:

             -   A catastrophic event that incapacitates the applicant’s ability to
                 manufacture a drug product, such as an explosion, a fire, or storm damage
                 to their manufacturing facilities.

             -   Events that could not have been reasonably foreseen by the applicant and
                 for which the applicant could not have planned, such as:

                    An abrupt discontinuation of the supply of an active ingredient, the
                     packaging material, or the product’s container closure system. If an
                     applicant experiences one or more of these discontinuations, the PAS
                     should document the date the applicant received notice of the
                     discontinuation.

                    The relocation of a facility or a change in an existing facility because
                     of a recent catastrophic event.




Originating Office: Office of Pharmaceutical Quality
Effective Date: 6/10/1999; 5/21/2018; 4/8/2021
                                                                                     Page 3 of 5

第 4 页

MANUAL OF POLICIES AND PROCEDURES

CENTER FOR DRUG EVALUATION AND RESEARCH                                 MAPP 5310.3 Rev. 2

RESPONSIBILITIES

    •   The OPQ Drug Shortage Coordinator will:

        o Act as OPQ’s point of contact for all drug shortage or potential drug shortage
          situations related to products mentioned in NDA PASs and BLA PASs.

        o Coordinate with the appropriate Drug Shortage Staff on expedited review
          requests related to drug shortages.

    •   The OPQ RBPM will:

        o For expedited requests related to an extraordinary hardship designation,
          collaborate with the appropriate Office of Product Quality Assessment
          (OPQA I, II, or III) supervisor about whether the situation meets the criteria
          for an extraordinary hardship, thereby ensuring a consistent designation.

        o For all other expedited requests, notify the supervisor of the expedited review
          request and how the request was received (i.e., whether FDA raised the
          request internally or whether the applicant made the request either in the
          original PAS or in an amendment).

        o Update Panorama with the expedited review request decision to either grant or
          deny the request. If the expedited review request is granted, the OPQ RBPM
          will document, in Panorama, the reason for the grant. If the expedited request
          based on a hardship claim is denied, the OPQ RBPM will document the
          reason for that denial.

        o Notify the requestor of the decision (i.e., whether the expedited review request
          was granted or denied).

        o Notify the OPQ quality assessment team of the expedited review status.

    •   The OPQA I, II, or III supervisor (or their designee) will:

        o For claims related to extraordinary hardship, work with the OPQ RBPM to
          determine whether the PAS should be expedited.

        o For all granted expedited requests, support the expedited review of the
          submission.

    •   The OPQA I, II, or III Assessment Team will:

        o Expedite the assessment of the submission if the expedited review


Originating Office: Office of Pharmaceutical Quality
Effective Date: 6/10/1999; 5/21/2018; 4/8/2021
                                                                                 Page 4 of 5

第 5 页

MANUAL OF POLICIES AND PROCEDURES

CENTER FOR DRUG EVALUATION AND RESEARCH                                        MAPP 5310.3 Rev. 2

             request is granted. If the expedited review request is denied, the
             assessment of the submission will follow OPQ’s established practices.


REFERENCES

    •   MAPP 5240.3 Rev. 6 Prioritization of the Review of Original ANDAs,
        Amendments, and Supplements. 4


EFFECTIVE DATE

This MAPP is effective upon date of publication.


CHANGE CONTROL TABLE

Effective     Revision Revision(s)
Date          Number
6/10/1999     Initial  N/A
5/21/2018     1        (1) Reflects OPQ’s roles and responsibilities for reviewing
                       expedited review requests for NDA and BLA PASs

                           (2) Updates the policy for processing FDA expedited review
                           requests for NDA and BLA PASs

                           (3) Renders obsolete the “Expedited Review Request
                           Documentation Form,” which was referenced in MAPP 5310.3
                           Requests for Expedited Review of NDA Chemistry Supplements
                           and was used to document an expedited review decision

                           (4) Addresses BLA PASs, which were not addressed in MAPP
                           5310.3 Requests for Expedited Review of NDA Chemistry
                           Supplements
4/8/2021      2            Updates to meet a statutory change
N/A           N/A          12/23/2024 administrative changes made to reflect changes in
                           OPQ’s suboffices’ names and leadership titles consistent with the
                           2024 OPQ reorganization




4
We update MAPPs periodically. To make sure you have the most recent version of a MAPP, check the
CDER Manual of Policies & Procedures web page at https://www.fda.gov/about-fda/center-drug-
evaluation-and-research-cder/cder-manual-policies-procedures-mapp.

Originating Office: Office of Pharmaceutical Quality
Effective Date: 6/10/1999; 5/21/2018; 4/8/2021
                                                                                         Page 5 of 5

来源:FDA 官方药品与生物制品信息 · fda.gov